Affymetrix & BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor Sam...
10 April 2013 - 8:30PM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) and BioDiscovery announce the
availability of the Nexus for OncoScan® Software for analysis of
whole genome copy number data generated from formalin-fixed,
paraffin-embedded (FFPE) solid tumor samples using the OncoScan®
FFPE Express 2.0 Service. Through a joint arrangement, this
software, based on BioDiscovery’s flagship Nexus Copy Number™, is
available to customers who are analyzing data generated using this
service.
Obtaining high-quality copy number data using limited amounts of
DNA from degraded FFPE samples is extremely challenging for cancer
researchers. Utilizing Affymetrix’ unique Molecular Inversion Probe
(MIP) technology, the OncoScan FFPE assay is capable of analyzing
highly degraded DNA in FFPE tumor samples, even from less than 100
ng of starting DNA material, and is currently available as a
service through Affymetrix Research Service Laboratory (ARSL) based
in Santa Clara, California.
OncoScan FFPE Express 2.0 Service has been successfully used by
more than 30 leading cancer research institutes, including M. D.
Anderson Cancer Center, University of California San Francisco, and
the Huntsman Cancer Institute at the University of Utah.
“Cancer translational researchers have been able to quickly and
easily analyze hundreds of degraded FFPE samples to correlate copy
number aberrations with outcomes data,” said Andy Last, Executive
Vice President of the Genetic Analysis and Clinical Applications
Business Unit at Affymetrix. “Nexus for OncoScan Software is
especially optimized for solid tumor copy number analysis and can
generate whole genome copy number calls from raw data in minutes.
We are very excited to continue to partner with BioDiscovery to
bring this powerful and easy-to-use software to the cancer research
community.”
"The OncoScan FFPE assay is an amazing technology for cancer
researchers allowing them to unlock DNA information from masses of
archived FFPE samples to obtain high quality data," said Soheil
Shams, President of BioDiscovery. “Combining the powerful OncoScan
FFPE technology with the proven power of Nexus Copy Number gives
scientists a unique solution that is sure to accelerate cancer
research, impact diagnosis, and ultimately lead to better patient
care and treatment. We are very pleased to partner with Affymetrix
in offering this powerful solution.”
A next generation OncoScan FFPE product will be available in
late 2013 enabling researchers to perform the assay and analysis in
their own lab. Delivering results in about 48 hours, this new
product will provide whole genome copy number coverage with high
resolution in known cancer genes, loss of heterozygozity (LOH) as
well as clinically relevant somatic mutation data - all from a
single assay. An updated version of Nexus for OncoScan Software
will be released in conjunction with the launch.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, and
OncoScan® trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
Products mentioned in this release are for research use only.
Not for diagnostic procedures.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2012, and other SEC reports for subsequent
quarterly periods.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness.
We strive to provide leadership and support, partnering with our
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest for answers toward using biology
for a better world.
More than 2,300 microarray systems have been shipped around the
world and more than 48,000 peer-reviewed papers have been published
citing our technologies. Affymetrix is headquartered in Santa
Clara, California, and has manufacturing facilities in Cleveland,
Ohio, San Diego, Vienna and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
About BioDiscovery, Inc.
BioDiscovery (www.biodiscovery.com) is a leader in the
development of breakthrough software and services for advanced copy
number variation and expression analysis, enabling customers in
drug discovery, research, and diagnostics by efficiently managing,
integrating, and analyzing data generated using high-throughput
microarray and next-generation sequencing technologies.
BioDiscovery Nexus Copy Number software offers simple yet
powerful tools for copy number and sequence variation analysis and
visualization from CGH arrays, SNP arrays, as well as
next-generation sequencing, for analysis of complex data such as
solid tumor samples. The elegant user-interface and powerful
statistical tools designed specifically for the end-user allow
detection of chromosomal aberrations and identification of affected
pathways with just a few mouse clicks.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024